About
Resilient serial entrepreneur with over a decade of experience in the fields of digital…
Articles by Rajiv
Activity
-
I'm DONE I'm done trying to fix a broken healthcare system. I'm done watching people suffer and die while they wait for care to be approved. I'm…
I'm DONE I'm done trying to fix a broken healthcare system. I'm done watching people suffer and die while they wait for care to be approved. I'm…
Liked by Rajiv Shrestha
-
There’s not a lot of details about the actual encounter in this case, so I’ll start by saying that the point of this post is not to place blame on…
There’s not a lot of details about the actual encounter in this case, so I’ll start by saying that the point of this post is not to place blame on…
Liked by Rajiv Shrestha
-
Weight-loss drugs like Ozempic and Wegovy are transforming lives – but they’re also creating new challenges for doctors. In this #USATODAY…
Weight-loss drugs like Ozempic and Wegovy are transforming lives – but they’re also creating new challenges for doctors. In this #USATODAY…
Liked by Rajiv Shrestha
Experience
Education
-
University of Massachusetts, Amherst
-
Dissertation title: Modeling the life span of red blood cells.
-
-
Thesis title: A mathematical model of acute response of
parathyroid hormone to changes in plasma ionized calcium in humans
Publications
-
Response of Red Blood Cell Folate to Supplementation in Nonpregnant Women is Predictable: A Proposal for Personalized Supplementation
Molecular Nutrition & Food Research
-
Models for the Red Blood Cell Lifespan
Journal of Pharmacokinetics and Pharmacodynamics
The lifespan of red blood cells (RBCs) plays an important role in the study and interpretation of various clinical conditions. Yet, confusion about the meanings of fundamental terms related to cell survival and their quantification still exists in the literature. To address these issues, we started from a compartmental model of RBC populations based on an arbitrary full lifespan distribution, carefully defined the residual lifespan, current age, and excess lifespan of the RBC population, and…
The lifespan of red blood cells (RBCs) plays an important role in the study and interpretation of various clinical conditions. Yet, confusion about the meanings of fundamental terms related to cell survival and their quantification still exists in the literature. To address these issues, we started from a compartmental model of RBC populations based on an arbitrary full lifespan distribution, carefully defined the residual lifespan, current age, and excess lifespan of the RBC population, and then derived the distributions of these parameters. For a set of residual survival data from biotin-labeled RBCs, we fit models based on Weibull, gamma, and lognormal distributions, using nonlinear mixed effects (NLME) modeling and parametric bootstrapping. From the estimated Weibull, gamma, and lognormal parameters we computed the respective population mean full lifes- pans (95% confidence interval): 115.60 (109.17-121.66), 116.71 (110.81-122.51), and 116.79 (111.23-122.75) days together with the standard deviations of the full lifespans: 24.77 (20.82-28.81), 24.30 (20.53-28.33), and 24.19 (20.43-27.73). We then estimated the 95th percentiles of the lifespan distributions (a surrogate for the maximum lifespan): 153.95 (150.02-158.36), 159.51 (155.09-164.00), and 160.40 (156.00-165.58) days, the mean current ages (or the mean residual lifespans): 60.45 (58.18-62.85), 60.82 (58.77-63.33), and 57.26 (54.33-60.61) days, and the residual half-lives: 57.97 (54.96-60.90), 58.36 (55.45-61.26), and 58.40 (55.62-61.37) days, for the Weibull, gamma, and lognormal models respectively. Corresponding estimates were obtained for the individual subjects. The three models provide equally excellent goodness-of-fit, reliable estimation, and physiologically plausible values of the directly interpretable RBC survival parameters.
Other authorsSee publication -
Control-Relevant Erythropoiesis Modeling in End-Stage Renal Disease
IEEE Transactions on Biomedical Engineering
Anemia is prevalent in end-stage renal disease (ESRD). The discovery of recombinant human erythropoietin (rHuEPO) over 30 years ago has shifted the treatment of anemia for patients on dialysis from blood transfusions to rHuEPO therapy. Many anemia management protocols (AMPs) used by clinicians comprise a set of experience-based rules for weekly-to monthly titration of rHuEPO doses based on hemoglobin (Hb) measurements. In order to facilitate the design of an AMP using model-based feedback…
Anemia is prevalent in end-stage renal disease (ESRD). The discovery of recombinant human erythropoietin (rHuEPO) over 30 years ago has shifted the treatment of anemia for patients on dialysis from blood transfusions to rHuEPO therapy. Many anemia management protocols (AMPs) used by clinicians comprise a set of experience-based rules for weekly-to monthly titration of rHuEPO doses based on hemoglobin (Hb) measurements. In order to facilitate the design of an AMP using model-based feedback control theory, we present a physiologically-relevant erythropoiesis model and demonstrate its applicability using clinical data.
Other authorsSee publication -
Estimating Intravascular and Interstitial Volumes at the Start of Hemodialysis Session
Conference: American Society of Nephrology Kidney Week 2014 Annual Meeting, At Philadelphia, PA, USA
Intradialytic hypotension is the most common hemodialysis (HD) complication and a significant cause of morbidity. Recent models of absolute blood volume in HD patients are based on bioimpedance, tracer dilution, relative blood volume measurements or combination thereof. The goal of this study was to investigate the feasibility of estimating pre-HD intravascular and interstitial volumes using Crit-Line data during routine HD conditions. Methods: We describe fluid volume dynamics during HD using…
Intradialytic hypotension is the most common hemodialysis (HD) complication and a significant cause of morbidity. Recent models of absolute blood volume in HD patients are based on bioimpedance, tracer dilution, relative blood volume measurements or combination thereof. The goal of this study was to investigate the feasibility of estimating pre-HD intravascular and interstitial volumes using Crit-Line data during routine HD conditions. Methods: We describe fluid volume dynamics during HD using a two-compartment model comprising intravascular and interstitial volumes. We used retrospective hematocrit (HCT) data (Crit-Line) collected every 20 seconds from 24 HD patients. Nonlinear regression was used to estimate model parameters over the initial HD period. Results: Pre-HD volumes were successfully estimated for all 24 data sets (Table1, Figure1). The mean (SD) time period required for successful estimation was 6.3 (3.4) min. The mean (SD) root
mean square estimation error of HCT was 0.13 (0.16). Conclusions: Crit-Line HCT data can be used to estimate pre-HD intravascular and interstitial volumes in HD patients. The minimal length of data required for estimation depends on the initial refill profile driven by unknown osmotic and hydrostatic pressures. These results should be tested in a study with a larger number of patients, and validated against gold standards of absolute blood volume measurements. These results may be used to better estimate dry weight for dialysis dose prescription and red cell mass in anemia management.
Estimating Intravascular and Interstitial Volumes at the Start of Hemodialysis Session. Available from: https://www.researchgate.net/publication/269096479_Estimating_Intravascular_and_Interstitial_Volumes_at_the_Start_of_Hemodialysis_Session [accessed Jun 9, 2015].Other authors -
A semi-mechanistic model of the time-course of release of PTH into plasma following administration of the calcytic JTT-305/MK-5442 in humans
Journal of bone and mineral research
JTT-305/MK-5442 is a Calcium Sensing Receptor (CaSR) allosteric antagonist being investigated for the treatment of osteoporosis. JTT-305/MK-5442 binds to CaSRs, thus preventing receptor activation by Ca2+. In the parathyroid gland, this results in the release of parathyroid hormone (PTH). Sharp spikes in PTH secretion followed by rapid returns to baseline are associated with bone formation, while sustained elevation in PTH is associated with bone resorption. We have developed a…
JTT-305/MK-5442 is a Calcium Sensing Receptor (CaSR) allosteric antagonist being investigated for the treatment of osteoporosis. JTT-305/MK-5442 binds to CaSRs, thus preventing receptor activation by Ca2+. In the parathyroid gland, this results in the release of parathyroid hormone (PTH). Sharp spikes in PTH secretion followed by rapid returns to baseline are associated with bone formation, while sustained elevation in PTH is associated with bone resorption. We have developed a semi-mechanistic, non-population model of the time-course relationship between JTT-305/MK-5442 and whole plasma PTH concentrations to describe both the secretion of PTH and the kinetics of its return to baseline levels. We obtained mean concentration data for JTT-305/MK-5442 and whole PTH from a multiple dose study in US postmenopausal women at doses of 5, 10, 15 and 20 mg. We hypothesized that PTH is released from two separate sources: a reservoir that is released rapidly (within minutes) in response to reduction in Ca2+ binding, and a second source released more slowly following hours of reduced Ca2+ binding. We modeled the release rates of these reservoirs as Emax functions of JTT-305/MK-5442 concentration. Our model describes both the dose-dependence of PTH Tmax and Cmax, and the extent and duration of the observed non-monotonic return of PTH to baseline levels following JTT-305/MK-5442 administration.
Other authors -
Book Title: Issues in Dialysis; Chapter 14: Update on Anemia and kidney disease
Nova publishers
Book Description:
Despite our efforts at creating clinical performance measures, clinical practice guidelines and intense government regulations, we still have disparities in care, poor outcomes and quality that is inferior to many other nations. Bundling and payment reform challenge the ability to deliver good care to patients even further. Chronic dialysis is at a crossroads. Physicians and providers must incorporate new approaches, reinventing the paradigm of how to plot the course of…Book Description:
Despite our efforts at creating clinical performance measures, clinical practice guidelines and intense government regulations, we still have disparities in care, poor outcomes and quality that is inferior to many other nations. Bundling and payment reform challenge the ability to deliver good care to patients even further. Chronic dialysis is at a crossroads. Physicians and providers must incorporate new approaches, reinventing the paradigm of how to plot the course of patient therapy. This book offers new ideas. It is refreshing, timely and engaging, with a wide range of topics by leading authors, each designed to help meet the challenges yet to come.Other authors -
Simplification of an Erythropoiesis Model for Design of Anemia Management Protocols in End Stage Renal Disease
Conf Proc IEEE Eng Med Biol Soc.
Abstract
Many end stage renal disease (ESRD) patients suffer from anemia due to insufficient endogenous production of erythropoietin (EPO). The discovery of recombinant human EPO (rHuEPO) over 30 years ago has shifted the treatment of anemia for patients on dialysis from blood transfusions to rHuEPO therapy. Many anemia management protocols (AMPs) used by clinicians comprise a set of experience-based rules for weekly-to-monthly titration of rHuEPO doses based on hemoglobin (Hgb)…Abstract
Many end stage renal disease (ESRD) patients suffer from anemia due to insufficient endogenous production of erythropoietin (EPO). The discovery of recombinant human EPO (rHuEPO) over 30 years ago has shifted the treatment of anemia for patients on dialysis from blood transfusions to rHuEPO therapy. Many anemia management protocols (AMPs) used by clinicians comprise a set of experience-based rules for weekly-to-monthly titration of rHuEPO doses based on hemoglobin (Hgb) measurements. In order to facilitate the design of an AMP based on formal control design methods, we present a physiologically-relevant erythropoiesis model, and show that its nonlinear dynamics can be approximated using a static nonlinearity, a step that greatly simplifies AMP design. We demonstrate applicability of our results using clinical data.Other authorsSee publication -
A Mathematical Model of Parathyroid Hormone Response to Changes in Plasma Ionized Calcium Concentration in Humans
Mathematical Biosciences
A complex bio-mechanism, commonly referred to as calcium homeostasis, regulates plasma ionized calcium (Ca2+) concentration in the human body within a narrow range which is crucial for maintaining normal physiology and metabolism. Taking a step towards creating a complete mathematical model of calcium homeostasis, we focus on the short-term dynamics of calcium homeostasis and consider the response of the parathyroid glands to acute changes in plasma Ca2+ concentration. We review available…
A complex bio-mechanism, commonly referred to as calcium homeostasis, regulates plasma ionized calcium (Ca2+) concentration in the human body within a narrow range which is crucial for maintaining normal physiology and metabolism. Taking a step towards creating a complete mathematical model of calcium homeostasis, we focus on the short-term dynamics of calcium homeostasis and consider the response of the parathyroid glands to acute changes in plasma Ca2+ concentration. We review available models, discuss their limitations, then present a two-pool, linear, time-varying model to describe the dynamics of this calcium homeostasis subsystem, the Ca–PTH axis. We propose that plasma PTH concentration and plasma Ca2+ concentration bear an asymmetric reverse sigmoid relation. The parameters of our model are successfully estimated based on clinical data corresponding to three healthy subjects that have undergone induced hypocalcemic clamp tests. In the first validation of this kind, with parameters estimated separately for each subject we test the model’s ability to predict the same subject’s induced hypercalcemic clamp test responses. Our results demonstrate that a two-pool, linear, time-varying model
with an asymmetric reverse sigmoid relation characterizes the short-term dynamics of the Ca–PTH axis.Other authors
Projects
-
A model of HbA1c response to changes in Fasting Plasma Glucose (FPG) due to a drug in diabetes patients
-
As a postdoc I built and validated a predictive mathematical model of HbA1c response to Merck's diabetes drug under development using their clinical trial data from various stages of development. Initial model was built on MATLAB. The final model was built and validated using NONMEM.
Languages
-
Nepali, Newari,
-
More activity by Rajiv
-
💊 GLP-1s: Are We Sacrificing Health by Ignoring Support? Last week, during a GP shift, I had a patient with a concern regarding the GLP-1…
💊 GLP-1s: Are We Sacrificing Health by Ignoring Support? Last week, during a GP shift, I had a patient with a concern regarding the GLP-1…
Liked by Rajiv Shrestha
-
𝗪𝗵𝗮𝘁 𝗗𝗼𝗲𝘀 𝗜𝘁 𝗠𝗲𝗮𝗻 𝘁𝗼 𝗕𝗲 𝗮 𝗗𝗼𝗰𝘁𝗼𝗿 𝗶𝗻 𝟮𝟬𝟮𝟱? Reflecting on ‘systemic issues’ on recent clinical shifts, I've been…
𝗪𝗵𝗮𝘁 𝗗𝗼𝗲𝘀 𝗜𝘁 𝗠𝗲𝗮𝗻 𝘁𝗼 𝗕𝗲 𝗮 𝗗𝗼𝗰𝘁𝗼𝗿 𝗶𝗻 𝟮𝟬𝟮𝟱? Reflecting on ‘systemic issues’ on recent clinical shifts, I've been…
Liked by Rajiv Shrestha
-
At Mass General Brigham, we’re transforming maternal health by delivering postnatal care directly to at-risk new parents through our Community Care…
At Mass General Brigham, we’re transforming maternal health by delivering postnatal care directly to at-risk new parents through our Community Care…
Liked by Rajiv Shrestha
-
“It sort of reminds me of when you board the airplane, how they always say if you have a child and the [oxygen] masks drop, you should put yours on…
“It sort of reminds me of when you board the airplane, how they always say if you have a child and the [oxygen] masks drop, you should put yours on…
Liked by Rajiv Shrestha
-
Proud of our community and the Hint Health team for passing this 1M active #DPC members on platform milestone. Transforming US healthcare starts…
Proud of our community and the Hint Health team for passing this 1M active #DPC members on platform milestone. Transforming US healthcare starts…
Liked by Rajiv Shrestha
-
Why do 59% of people say they’re “satisfied” with their health insurance — even when the system feels so broken? As my friend Dean Jargo noted, most…
Why do 59% of people say they’re “satisfied” with their health insurance — even when the system feels so broken? As my friend Dean Jargo noted, most…
Liked by Rajiv Shrestha
-
Fatima Cody Stanford, a leading physician-scientist and tireless advocate in obesity medicine, sharing the stage with Dave Ricks, Chair/CEO of Eli…
Fatima Cody Stanford, a leading physician-scientist and tireless advocate in obesity medicine, sharing the stage with Dave Ricks, Chair/CEO of Eli…
Shared by Rajiv Shrestha
-
Proud is the word. The eight startups in our second Social Impact Cohort (first early-stage group) graduated today, and I am simply speechless at…
Proud is the word. The eight startups in our second Social Impact Cohort (first early-stage group) graduated today, and I am simply speechless at…
Liked by Rajiv Shrestha
-
What's wrong with this picture? While it looks like we have the Greater Tampa Bay and Orlando areas covered with DPC practices, we have one little…
What's wrong with this picture? While it looks like we have the Greater Tampa Bay and Orlando areas covered with DPC practices, we have one little…
Liked by Rajiv Shrestha
-
“Our conventional approach to health care tends to separate patients’ health by body system, treating each independently and “efficiently”—e.g.…
“Our conventional approach to health care tends to separate patients’ health by body system, treating each independently and “efficiently”—e.g.…
Liked by Rajiv Shrestha
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Rajiv Shrestha in United States
-
Rajiv Shrestha
Business Systems Analyst
-
Rajiv Shrestha
Principal Software Engineer at Cotiviti
-
Rajiv Shrestha
-
Rajiv Shrestha
Technical Support Analyst
9 others named Rajiv Shrestha in United States are on LinkedIn
See others named Rajiv Shrestha